SPOTLIGHT: AstraZeneca buys Canadian facility

AstraZeneca has beefed up its biotech side with the purchase of Royal DSM's biologics manufacturing facility in Canada. AstraZeneca plans to use the 66,000-square-foot site to make antibodies for clinical testing. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.